Results 61 to 70 of about 169,886 (331)

Potential novel therapy targets in neuroendocrine carcinomas of the breast [PDF]

open access: yes, 2018
Neuroendocrine carcinoma (NEC) of the breast is a rare, special type of breast cancer, reportedly constituting 2% to 5% of all breast cancers. Although breast NEC does not have a specific targeted therapy, several new targeted therapies based on specific
Contreras, Elma   +7 more
core   +2 more sources

Metastasizing esthesioneuroblastoma in a dog [PDF]

open access: yes, 2014
A 7-year-old Afghan hound presented with a history of disorientation, loss of vision, and seizures. Magnetic resonance imaging helped identify a mass at the level of the main olfactory bulb that compressed and displaced adjacent tissues in the cribriform
Herden, Christiane   +3 more
core   +1 more source

IGF-I influences everolimus activity in medullary thyroid carcinoma [PDF]

open access: yes, 2015
Context: Medullary thyroid carcinoma (MTC) is a rare tumor originating from thyroid parafollicular C cells. It has been previously demonstrated that insulin-like growth factor I (IGF-I) protects MTC from the effects of antiproliferative drugs. Everolimus,
degli Uberti, Ettore C.   +9 more
core   +1 more source

Metastatic neuroendocrine carcinoma to the mandibular gingiva from the duodenum papilla

open access: yesOral Oncology Reports, 2023
Neuroendocrine carcinoma is a high-grade carcinoma with morphological and immunohistochemical features of neuroendocrine differentiation. Poorly differentiated neuroendocrine carcinoma which has two subtypes (small cell or large cell type) is extremely ...
Toshinori Iwai   +3 more
doaj   +1 more source

Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/ mTOR axis in metastatic pheochromocytoma/ paraganglioma [PDF]

open access: yes, 2019
Artículo escrito por un elevado número de autores, solo se referencian el que aparece en primer lugar y los autores pertenecientes a la UAMPheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors that present variable outcomes.
Alvarez - Escola, Cristina   +1 more
core   +2 more sources

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

open access: yesMolecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts   +8 more
wiley   +1 more source

MEN1 Deficiency‐Driven Activation of the β‐Catenin‐MGMT Axis Promotes Pancreatic Neuroendocrine Tumor Growth and Confers Temozolomide Resistance

open access: yesAdvanced Science
O6‐methylguanine DNA methyltransferase (MGMT) removes alkyl adducts from the guanine O6 position (O6‐MG) and repairs DNA damage. High MGMT expression results in poor response to temozolomide (TMZ).
Junfeng Xu   +16 more
doaj   +1 more source

miR375-3p Distinguishes Low-Grade Neuroendocrine From Non-neuroendocrine Lung Tumors in FFPE Samples

open access: yesFrontiers in Molecular Biosciences, 2020
Lung cancer is still one of the leading cause of death worldwide. The clinical variability of lung cancer is high and drives treatment decision. In this context, correct discrimination of pulmonary neuroendocrine tumors is still of critical relevance ...
Simone Detassis   +12 more
doaj   +1 more source

Correlation of Matrix Metalloproteinases and Tissue Inhibitors of Matrix Metalloproteinase Expression in Ileal Carcinoids, Lymph Nodes and Liver Metastasis with Prognosis and Survival [PDF]

open access: yes, 2009
Purpose: Ileal carcinoids are gut epithelial tumors originating from serotonin-containing enterochromaffin (EC) cells. Therapeutic options for effectively inhibiting the growth and spread of metastatic carcinoids are still limited.
Baur, Dorothee M.   +8 more
core   +2 more sources

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

open access: yesMolecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy